{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:48:47Z","timestamp":1761162527711,"version":"build-2065373602"},"reference-count":48,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":3243,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:p>\n                    <jats:bold>Objectives.<\/jats:bold>\n                    To discuss specific facts regarding use as a bioweapon, epidemiology, microbiology, clinical manifestations, diagnosis, antimicrobial therapy, immunization, and isolation precautions for five most likely agents of bioterrorism; to review and provide recommendations for health care clinicians on the management of these bioterrorism agents; and to share information on the pharmacist's role in preparedness and response.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Participants.<\/jats:bold>\n                    The manuscript was drafted by the three authors, reviewed by a group of selected members of the Society of Infectious Diseases Pharmacists, and approved by its Board of Directors.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Evidence.<\/jats:bold>\n                    The primary focus was to review and summarize recent and key articles on bioterrorism. Preference was given to peer\u2010reviewed journal information and government\u2010sponsored journals, such as the\n                    <jats:italic>MMWR, Morbidity and Mortality Weekly Report.<\/jats:italic>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Consensus Process.<\/jats:bold>\n                    Written comments were requested from each reviewer. Comments were incorporated into the final draft.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    Pharmacists play an integral role in disaster preparedness and response and should be involved in planning committees. As drug information specialists, pharmacists can assist other health care providers and emergency personnel, as well as provide counseling to calm, comfort, and empower the public.\n                  <\/jats:p>","DOI":"10.1592\/phco.23.3.274.32097","type":"journal-article","created":{"date-parts":[[2004,5,11]],"date-time":"2004-05-11T07:27:08Z","timestamp":1084260428000},"page":"274-290","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bioterrorism: Pivotal Clinical Issues: Consensus Review of the Society of Infectious Diseases Pharmacists"],"prefix":"10.1002","volume":"23","author":[{"given":"Colleen M.","family":"Terriff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben M.","family":"Lomaestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550050051033"},{"key":"e_1_2_1_3_2","first-page":"787","article-title":"Bioterrorism alleging use of anthrax and interim guidelines for management: United States, 1998","volume":"281","author":"Centers for Disease Control and Prevention.","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"e_1_2_1_4_2","first-page":"1","article-title":"Biological and chemical terrorism: strategic plan for preparedness and response\u2014recommendations of the CDC strategic planning workgroup","volume":"49","author":"Centers for Disease Control and Prevention.","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973702"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_2_1_7_2","first-page":"941","article-title":"Update: investigation of bioterrorism\u2010related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax, November 2001","volume":"50","author":"Centers for Disease Control and Prevention.","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0802.01-0521"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.102691499"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0706.010604"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.7.863"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.9.690.31543"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411107"},{"key":"e_1_2_1_14_2","first-page":"909","article-title":"Update: investigation of bioterrorism\u2010related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 26, 2001","volume":"50","author":"Centers for Disease Control and Prevention.","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.18.1735"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1766-1766.2000"},{"key":"e_1_2_1_18_2","first-page":"56","volume-title":"Antimicrobial therapy for Bacillus anthracis\u2010induced mixed infection in 60Co\u2010gamma\u2010irradiated mice [abstr]","author":"Elliott TB","year":"2000"},{"key":"e_1_2_1_19_2","first-page":"167","volume-title":"In vitro activity of daptomycin, sparfloxacin, quinupristin\u2010dalfopristin and other antibiotics against Bacillus anthracis strains [abstr]","author":"Heine HS","year":"2000"},{"key":"e_1_2_1_20_2","first-page":"173","volume-title":"In vitro activity of oritavancin (LY333328), levofloxacin, meropenem, GAR 936 and linezolid against strains of Bacillus anthracis [abstr]","author":"Heine HS","year":"2001"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra012892"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.7.869"},{"key":"e_1_2_1_23_2","unstructured":"BartlettJG.What's hot and what's not. Presented at the 39th annual meeting of the Infectious Diseases Society of America San Francisco CA October 26 2001. Summarized by David Haburchak. Available fromwww.medscape.com. Accessed January 15 2003."},{"key":"e_1_2_1_24_2","first-page":"984","article-title":"Considerations for distinguishing influenza\u2010like illness from inhalational anthrax","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"volume-title":"FDA briefing package. Antiinfective drug products advisory committee meeting","year":"2000","author":"Food and Drug Administration.","key":"e_1_2_1_25_2"},{"key":"e_1_2_1_26_2","first-page":"889","article-title":"Update: investigation of anthrax associated with intentional exposure an interim public health guidelines, October 2001","volume":"50","author":"Centers for Disease Control and Prevention.","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A424"},{"key":"e_1_2_1_28_2","first-page":"973","article-title":"Update: Investigation of bioterrorism\u2010related anthrax and adverse events from antimicrobial prophylaxis","volume":"50","author":"Centers for Disease Control and Prevention.","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"volume-title":"Medical management of biological casualties handbook","year":"2001","author":"U.S. Army Medical Research Institute of Infectious Diseases.","key":"e_1_2_1_29_2"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.8.1059"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550050061035"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550050095041"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/318513"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.17.2281"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)80110-2"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/318509"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.18.1735"},{"key":"e_1_2_1_38_2","unstructured":"McKinneyWP BiaFJ StewartC et al.Bioterrorism: an update for clinicians pharmacists and emergency management planners. Emerg Med Consensus ReportsNov 1 2001;8\u20139. Available fromwww.ahcpub.comahc_root_htmlhotarchivehic0300.html. Accessed June 1 2002."},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390811"},{"volume-title":"Biohazard","year":"1999","author":"Alibek K","key":"e_1_2_1_40_2"},{"key":"e_1_2_1_41_2","first-page":"8.7.4","volume-title":"Infectious diseases","author":"Buller RM","year":"2000"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196911272812201"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020534"},{"key":"e_1_2_1_44_2","first-page":"27","volume-title":"Air Force Magazine","author":"Chapman S","year":"2002"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400036536"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2763"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011374"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/ajhp\/59.10.928","article-title":"Bioterrorism preparedness: answers for the health\u2010system pharmacist","volume":"59","author":"Teeter DS","year":"2002","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ajhp\/58.3.233","article-title":"Citywide pharmaceutical preparation for bioterrorism","volume":"58","author":"Terriff CM","year":"2001","journal-title":"Am J Health-Syst Pharm"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.23.3.274.32097","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.23.3.274.32097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:00:25Z","timestamp":1761066025000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.23.3.274.32097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1592\/phco.23.3.274.32097"],"URL":"https:\/\/doi.org\/10.1592\/phco.23.3.274.32097","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}